ArticleCancer research communications2023

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor.

Shruti Lal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.